Loading company
Profusa, Inc.
PFSA · Nasdaq · ·
$2.24+29.5%Sep 29 close
- 1M
- -23.5%
- 6M
- -95.7%
- 1Y
- -99.9%
PFSA · Nasdaq · ·
$2.24+29.5%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$8.8M | -$2.3M | -272.87% |
| Profit per share | -$2.05 | -$0.07 | -2,828.57% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Profusa, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Profusa is a digital health company developing a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable, and affordable biosensors and intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Profusa, Inc.’s Item 2.02 8-K filed August 20, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.